On March 8, 2024, the Board of Directors of Assertio Holdings, Inc. appointed Sigurd Kirk to the Board, effective April 3, 2024 (the ?Effective Date?). In connection with his appointment to the Board, Mr. Kirk was appointed as a member of the Audit Committee and Compensation Committee of the Board, effective as of the Effective Date. Mr. Kirk, 57, is a senior corporate business development executive with more than 20 years of pharmaceutical experience in the areas of branded biopharmaceutical, medical device and generic products.

Since 2021, Mr. Kirk has served as a consultant and director to privately-held pharmaceutical companies and, from May 2021 to January 2024, served as a director and member of the audit committee of Aravive, Inc., a development stage oncology company. From 2009 until its acquisition by AbbVie Inc. in May 2020, Mr. Kirk held various positions at Allergan plc. (formerly Actavis), a pharmaceutical company.

From May 2012 until May 2020, Mr. Kirk was Executive Vice President, Corporate Business Development at Allergan plc., where he was a member of the Executive Leadership Team. He was an integral member assessing development and commercial opportunities, leading due diligence, as well as negotiating and transacting key legal and financial terms. Mr. Kirk also served as Senior Vice President, Global Controller and Chief Accounting Officer for Barr Pharmaceuticals, Inc. from 2003 until 2009. Mr. Kirk started his career at Deloitte & Touche as an Audit Manager, earning his CPA certification.

The Board considered Mr. Kirk?s experience and expertise within the following areas relevant to the Company and its business in concluding that he should serve on the Board: Business Development, Acquisitions, Divestitures, Licensing Markets, Financial Planning & Analysis, and Board and Board committee experience. Mr. Kirk received his Bachelor of Business Administration degree from Pace University.